YU91403A - Antitela specifična za cd44v6 - Google Patents
Antitela specifična za cd44v6Info
- Publication number
- YU91403A YU91403A YU91403A YUP91403A YU91403A YU 91403 A YU91403 A YU 91403A YU 91403 A YU91403 A YU 91403A YU P91403 A YUP91403 A YU P91403A YU 91403 A YU91403 A YU 91403A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- antibody
- antibody proteins
- cd44v6
- antibodies specific
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Predmetni pronalazak pripada oblasti onkologije. Pronalazak se odnosi na antitela sa specifikovanom sekvencom koja su specifična za epitop koji je kodiran sa varijantom egzona v6 gena CD44 i na derivate pomenutog antitela. Pronalazak se takodje odnosi i na molekule nukleinskih kiselina koji kodiraju pomenute proteine antitela. Pronalazak pored toga obuhvata i postupke za dobijanje pomenutih proteina antitela. Osim toga, pronalaskom su takodje realizovane i farmaceutske kompozicije koje sadrže pomenute proteine antitela. Pored toga, pronalazak se dalje odnosi i na njihovu primenu za dobijanje leka za lečenje raka.[The present invention belongs to the field of oncology. The invention relates to antibodies with specified sequence which are specific for an epitope which is coded by the variant exon v6 of the CD44 gene and to derivatives of said antibody. The invention also provides nucleic acid molecules encoding said antibody proteins. The invention furthermore pertains to methods for producing said antibody proteins. The invention also provides pharmaceutical compositions comprising said antibody proteins. The invention furthermore is concerned with the use in the manufacture of a medicament for the treatment of cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01112237 | 2001-05-18 | ||
US32514701P | 2001-09-26 | 2001-09-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
YU91403A true YU91403A (sh) | 2006-05-25 |
Family
ID=33442672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YU91403A YU91403A (sh) | 2001-05-18 | 2002-05-17 | Antitela specifična za cd44v6 |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1397387A1 (sh) |
JP (1) | JP2005504517A (sh) |
CN (1) | CN1541226A (sh) |
AR (1) | AR036154A1 (sh) |
BR (1) | BR0210905A (sh) |
CA (1) | CA2443437A1 (sh) |
CZ (1) | CZ20033476A3 (sh) |
EA (1) | EA200301169A1 (sh) |
EC (1) | ECSP034838A (sh) |
EE (1) | EE200300569A (sh) |
HU (1) | HUP0400030A3 (sh) |
MX (1) | MXPA03010523A (sh) |
PE (1) | PE20021098A1 (sh) |
PL (1) | PL365735A1 (sh) |
SK (1) | SK15592003A3 (sh) |
WO (1) | WO2002094879A1 (sh) |
YU (1) | YU91403A (sh) |
ZA (1) | ZA200307365B (sh) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7189397B2 (en) | 1999-10-08 | 2007-03-13 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US7947496B2 (en) | 1999-10-08 | 2011-05-24 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US8071072B2 (en) | 1999-10-08 | 2011-12-06 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US8048416B2 (en) | 1999-10-08 | 2011-11-01 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US20050100542A1 (en) | 1999-10-08 | 2005-05-12 | Young David S. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
EP2316857A1 (en) * | 2004-02-12 | 2011-05-04 | Morphotek, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
WO2006099141A2 (en) | 2005-03-10 | 2006-09-21 | Morphotek, Inc. | Anti-mesothelin antibodies |
JP2009521206A (ja) | 2005-04-22 | 2009-06-04 | モルフォテック、インク. | 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体 |
WO2008157369A2 (en) * | 2007-06-13 | 2008-12-24 | Zymogenetics, Inc. | Use of taci-ig fusion protein such as atacicept for the manufacture of a medicament for treating lupus erythematosus |
EP2009028A1 (en) * | 2007-06-27 | 2008-12-31 | Monoclonal Antibodies Therapeutics | Combination of a conventional anti-cancer treatment with anti-CD44 antibody administration for treating solid tumors |
CA2786337A1 (en) | 2010-02-04 | 2011-08-11 | F. Hoffmann-La Roche Ag | A monoclonal antibody to cd44 for use in the treatment of head and neck squamous cell carcinoma |
CN102337298B (zh) * | 2011-08-19 | 2013-11-06 | 黄开红 | 一种输送siRNA的免疫纳米载体及其制备方法和应用 |
EP2788024A1 (en) | 2011-12-06 | 2014-10-15 | F.Hoffmann-La Roche Ag | Antibody formulation |
WO2017215637A1 (zh) * | 2016-06-15 | 2017-12-21 | 李翀 | 一种人子宫内膜癌的标志物、抗体及其应用 |
CN107556388A (zh) * | 2016-06-30 | 2018-01-09 | 中国科学院深圳先进技术研究院 | 抗CD44v6和CD3特异性双靶向抗体、含该双靶向抗体表达盒的微环DNA及应用 |
JP2024512324A (ja) * | 2021-03-05 | 2024-03-19 | ジーオー セラピューティクス,インコーポレイテッド | 抗グリコcd44抗体およびその使用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0438310A1 (en) * | 1990-01-19 | 1991-07-24 | Merck & Co. Inc. | Method for producing recombinant immunoglobuline |
GB9020282D0 (en) * | 1990-09-17 | 1990-10-31 | Gorman Scott D | Altered antibodies and their preparation |
CA2149635A1 (en) * | 1992-11-20 | 1994-06-09 | David Tarin | Peptide corresponding to cd44 exon 6, antibodies specific for said peptide and use of these antibodies for diagnosis of tumors |
UA58482C2 (uk) * | 1994-06-08 | 2003-08-15 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти |
UY24389A1 (es) * | 1995-12-06 | 2001-10-25 | Karlsruhe Forschzent | Composición farmacéutica para el tratamiento de carcinoma de epitelio plano |
-
2002
- 2002-05-17 EE EEP200300569A patent/EE200300569A/xx unknown
- 2002-05-17 WO PCT/EP2002/005467 patent/WO2002094879A1/en not_active Application Discontinuation
- 2002-05-17 CA CA002443437A patent/CA2443437A1/en not_active Abandoned
- 2002-05-17 MX MXPA03010523A patent/MXPA03010523A/es unknown
- 2002-05-17 AR ARP020101830A patent/AR036154A1/es not_active Suspension/Interruption
- 2002-05-17 YU YU91403A patent/YU91403A/sh unknown
- 2002-05-17 PL PL02365735A patent/PL365735A1/xx not_active Application Discontinuation
- 2002-05-17 HU HU0400030A patent/HUP0400030A3/hu unknown
- 2002-05-17 EP EP02735364A patent/EP1397387A1/en not_active Ceased
- 2002-05-17 EA EA200301169A patent/EA200301169A1/ru unknown
- 2002-05-17 CN CNA028101561A patent/CN1541226A/zh active Pending
- 2002-05-17 JP JP2002592353A patent/JP2005504517A/ja active Pending
- 2002-05-17 CZ CZ20033476A patent/CZ20033476A3/cs unknown
- 2002-05-17 SK SK1559-2003A patent/SK15592003A3/sk not_active Application Discontinuation
- 2002-05-17 PE PE2002000422A patent/PE20021098A1/es not_active Application Discontinuation
- 2002-05-17 BR BR0210905-0A patent/BR0210905A/pt not_active Expired - Fee Related
-
2003
- 2003-09-22 ZA ZA200307365A patent/ZA200307365B/xx unknown
- 2003-11-10 EC EC2003004838A patent/ECSP034838A/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2002094879A1 (en) | 2002-11-28 |
HUP0400030A3 (en) | 2006-02-28 |
CA2443437A1 (en) | 2002-11-28 |
ZA200307365B (en) | 2004-05-10 |
MXPA03010523A (es) | 2004-07-01 |
EP1397387A1 (en) | 2004-03-17 |
EA200301169A1 (ru) | 2004-06-24 |
BR0210905A (pt) | 2004-06-08 |
PL365735A1 (en) | 2005-01-10 |
JP2005504517A (ja) | 2005-02-17 |
SK15592003A3 (sk) | 2004-06-08 |
AR036154A1 (es) | 2004-08-18 |
CN1541226A (zh) | 2004-10-27 |
ECSP034838A (es) | 2003-12-24 |
HUP0400030A2 (hu) | 2004-04-28 |
CZ20033476A3 (cs) | 2004-05-12 |
PE20021098A1 (es) | 2003-02-11 |
EE200300569A (et) | 2004-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA03010523A (es) | Anticuerpos especificos para cd44v6. | |
SG170080A1 (en) | Human monoclonal antibodies to o8e | |
WO2007067730A3 (en) | Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use | |
WO2007067992A3 (en) | Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 | |
SG10201408073XA (en) | Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target | |
ATE516047T1 (de) | Ovr110-antikörperzusammensetzungen und anwendungsverfahren | |
SG163554A1 (en) | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) | |
ATE462726T1 (de) | Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür | |
UA97516C2 (ru) | Полностью человеческое моноклональное антитело против vap-1 | |
EA200800094A1 (ru) | Антитела cd19 и их использование | |
WO2008076560A3 (en) | Human monoclonal antibodies to btla and methods of use | |
ATE420160T1 (de) | Modifizierte rekombinante vacciniaviren, verwendungen davon | |
IL176007A0 (en) | Antibodies specific to c35 and pharmaceutical compositions containing the same | |
WO2005097185A3 (en) | Irta-5 antibodies and their uses | |
WO2006076691A3 (en) | Irta-2 antibodies and their uses | |
WO2002083171A3 (en) | Cancer treatment by using fap-alpha specific antibodies | |
HK1094876A1 (en) | Method of producing recombinant antibodies against tumours | |
ATE514718T1 (de) | Peptabody für krebsbehandlung | |
AU2002318934A1 (en) | Sak: modulation of cellular proliferation for treatment of cancer | |
UY27298A1 (es) | Anticuerpos específicos de cd44v6 | |
PT914417E (pt) | Dnase ii humana | |
IL149045A0 (en) | Diagnosis and therapy of cancer using sgp28-related molecules | |
ATE463566T1 (de) | Tumor- und seneszenzsmarker | |
BR0210835A (pt) | Moléculas de agrecanase | |
WO2006039135A3 (en) | Irta-4 antibodies and their uses |